MAINZ BIOMED NV (MYNZ)
NL0015000LC2 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 580K 18.37% | 530K -8.62% | 895.48K 68.96% | 1.092M 21.95% | 1.428M 30.77% | 9.384M 557.14% | 45.703M 387.03% | 105.63M 131.12% | 181.16M 71.50% | 286.72M 58.27% | 428.11M 49.31% | |
| EBITDA YoY % growth | -9.65M -1,456.45% | -26.13M -170.78% | -25.778M 1.35% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -9.72M -1,329.41% | -26.51M -172.74% | -26.645M -0.51% | -16.705M 37.31% | -15.871M 4.99% | -29.988M -88.95% | -41.75M -39.22% | -4.761M 88.60% | 45.342M 1,052.29% | 113.62M 150.58% | 157.43M 38.56% | |
| Operating Margin | -1,675.86% | -5,001.89% | -2,975.46% | -1,529.72% | -1,111.43% | -319.57% | -91.35% | -4.51% | 25.03% | 39.63% | 36.77% | |
| EPS YoY % growth | N/A | N/A | -1.64 97.65% | -24.07 -1,367.80% | -9.38 61.02% | -0.66 92.93% | -0.32 52.31% | -0.04 87.10% | 0.27 750.00% | 0.66 150.00% | 0.92 38.46% |
All data in USD
| Q3 / 24 | Q4 / 24 | |
|---|---|---|
| EPS Q2Q % growth | -0.20 49.00% | -0.20 17.12% |
| Revenue Q2Q % growth | 331.5K 83.15% | 357K 66.82% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -6.685M -18.52% | -7.028M -6.64% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 59.02% | -0.23 | % | |
| Q1 2024 Q2Q % growth | -0.24 46.67% | -0.26 | 0.02 | 5.88% |
| Q4 2023 Q2Q % growth | -0.24 48.85% | -0.32 | 0.08 | 25.70% |
| Q3 2023 Q2Q % growth | -0.39 11.08% | -0.48 | 0.09 | 19.22% |
| Q2 2023 Q2Q % growth | -0.56 -19.35% | -0.43 | -0.13 | -30.72% |
| Q1 2023 Q2Q % growth | -0.45 9.96% | -0.44 | -0.01 | -3.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 520.77K 109.99% | 306K | 214.77K | 70.19% |
| Q1 2024 Q2Q % growth | -8.20% | 229.5K | % | |
| Q4 2023 Q2Q % growth | 214K -26.22% | 275.4K | -61.4K | -22.29% |
| Q3 2023 Q2Q % growth | 181K -9.00% | 338.303K | -157.303K | -46.50% |
| Q2 2023 Q2Q % growth | 248K 3.42% | 299.197K | -51.197K | -17.11% |
| Q1 2023 Q2Q % growth | 250K | 374.003K | -124.003K | -33.16% |
| Q4 2022 Q2Q % growth | 290.07K -49.76% | 183.6K | 106.47K | 57.99% |
| Q2 2022 Q2Q % growth | 239.81K -42.53% | 153K | 86.81K | 56.74% |
| Q1 2022 Q2Q % growth | 107.1K | -107.1K | -100.00% | |
| Q4 2021 Q2Q % growth | 577.35K 16.97% | % | ||
| Q2 2021 Q2Q % growth | 417.31K 150.34% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 13.33% | -2597.14% | -2597.14% |
| Revenue | 0% | -47.37% | -10.78% | -10.78% |